|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
2
|
|
pubmed:dateCreated |
2005-2-15
|
|
pubmed:abstractText |
Rituximab, an anti-CD20 monoclonal antibody that depletes CD20(+) B cells, has demonstrated efficacy in peripheral neurological diseases. Whether this efficacy can be translated to neurological diseases of the central nervous system with possible autoimmune B-cell involvement remains unknown.
|
|
pubmed:grant |
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Feb
|
|
pubmed:issn |
0003-9942
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
62
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
258-64
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:15710854-Adult,
pubmed-meshheading:15710854-Antibodies,
pubmed-meshheading:15710854-Antibodies, Monoclonal,
pubmed-meshheading:15710854-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:15710854-Antigens, CD19,
pubmed-meshheading:15710854-Antigens, CD20,
pubmed-meshheading:15710854-B-Lymphocytes,
pubmed-meshheading:15710854-Chi-Square Distribution,
pubmed-meshheading:15710854-Female,
pubmed-meshheading:15710854-Flow Cytometry,
pubmed-meshheading:15710854-Humans,
pubmed-meshheading:15710854-Middle Aged,
pubmed-meshheading:15710854-Multiple Sclerosis, Chronic Progressive
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Effect of rituximab on the peripheral blood and cerebrospinal fluid B cells in patients with primary progressive multiple sclerosis.
|
|
pubmed:affiliation |
Department of Neurology and Center for Immunology, The University of Texas Southwestern Medical Center, Dallas 75390, USA. nancy.monson@utsouthwestern.edu
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Comparative Study,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|
